Page last updated: 2024-08-24

tenofovir and zoledronic acid

tenofovir has been researched along with zoledronic acid in 8 studies

Research

Studies (8)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (37.50)29.6817
2010's3 (37.50)24.3611
2020's2 (25.00)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M1
Hussar, DA1
Carr, A; Ebeling, PR; Hoy, JF; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J1
Carr, A; Ebeling, P; Hoy, J; Kerr, SJ; Martinez, E; Pocock, N; Richardson, R; Rojas, J1
Duan, L; Li, XF; Lin, W; Liu, JZ; Ren, DC; Song, M; Zhan, ZR1

Reviews

1 review(s) available for tenofovir and zoledronic acid

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

3 trial(s) available for tenofovir and zoledronic acid

ArticleYear
Zoledronic acid is superior to tenofovir disoproxil fumarate-switching for low bone mineral density in adults with HIV.
    AIDS (London, England), 2018, 09-10, Volume: 32, Issue:14

    Topics: Absorptiometry, Photon; Adult; Aged; Anti-HIV Agents; Australia; Bone Density; Bone Density Conservation Agents; Bone Diseases, Metabolic; Drug Substitution; Female; Femur Neck; HIV Infections; Humans; Lumbar Vertebrae; Male; Middle Aged; Spain; Tenofovir; Treatment Outcome; Viral Load; Zoledronic Acid

2018
Prolonged Effect of Zoledronic Acid on Bone Mineral Density and Turnover in HIV-Infected Adults on Tenofovir: A Randomized, Open-Label Study.
    Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2019, Volume: 34, Issue:12

    Topics: Adult; Biomarkers; Bone Density; Bone Remodeling; Female; Fractures, Bone; HIV Infections; Humans; Male; Middle Aged; Tenofovir; Treatment Outcome; Zoledronic Acid

2019
Administration of zoledronic acid alleviates osteoporosis in HIV patients by suppressing osteoclastogenesis via regulating RANKL expression.
    Molecular medicine (Cambridge, Mass.), 2021, 02-26, Volume: 27, Issue:1

    Topics: Adult; Anti-Retroviral Agents; Bone Density; Bone Density Conservation Agents; Cell Proliferation; Cells, Cultured; Cyclic AMP-Dependent Protein Kinase Catalytic Subunits; Female; HIV Infections; Humans; Male; MAP Kinase Signaling System; MicroRNAs; Middle Aged; Osteoclasts; Osteogenesis; Osteoporosis; RANK Ligand; Smad3 Protein; Tenofovir; Zoledronic Acid

2021

Other Studies

4 other study(ies) available for tenofovir and zoledronic acid

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
    Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3

    Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries

2023
New drugs 2002, part III.
    Nursing, 2002, Volume: 32, Issue:7

    Topics: Adenine; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Infective Agents; Antihypertensive Agents; Antirheumatic Agents; Bone Resorption; Bosentan; Cephalosporins; Darbepoetin alfa; Diphosphonates; Drug Approval; Drug Therapy; Drug-Related Side Effects and Adverse Reactions; Erythropoietin; Heart Failure; Humans; Hypoglycemic Agents; Imidazoles; Indoles; Insulin; Insulin Aspart; Interleukin 1 Receptor Antagonist Protein; Natriuretic Agents; Natriuretic Peptide, Brain; Organophosphonates; Organophosphorus Compounds; Protein C; Recombinant Proteins; Serotonin Receptor Agonists; Sialoglycoproteins; Sulfonamides; Tenofovir; Tryptamines; Zoledronic Acid

2002